Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-02-28

Clinical Trial Update: A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) [Phase 2]

View source ↗

Summary

Phase 2 study of belzutifan (MK-6482) in participants with advanced renal cell carcinoma; results have been posted and the trial is currently active but not rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Belzutifan (belzutifan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Carcinoma, Renal Cell | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-02-28